See related research by Mecott *et al.*, <http://ccforum.com/content/14/4/R153>

In the previous issue of *Critical Care*Mecott and colleagues report the effects of a glucagon-like peptide-1 (GLP-1) analogue, exenatide, on glycaemia in severely burned paediatric patients \[[@B1]\]. The incretin hormones, GLP-1 and glucose-dependent polypeptide (GIP), mediate \~70% of the insulin response to a meal \[[@B2]\]. While GIP is potently insulinotropic in health, its effect is markedly attenuated in type 2 diabetic patients, such that even pharmacological doses have little effect on glycaemia \[[@B3]\]. In contrast, physiological replacement or pharmaco-logical administration of GLP-1 lowers glycaemia substantially in this group \[[@B3]\]. Accordingly, studies in ambulant type 2 diabetic patients have focused on the therapeutic potential administration of GLP-1 rather than GIP. Significantly, the glucose-lowering effects of exogenous GLP-1 are glucose dependent, such that even pharmacological doses of GLP-1 are most unlikely to cause hypoglycaemia.

Native GLP-1 is not used as a glucose-lowering agent in ambulant type 2 diabetic patients because of the necessity for continuous administration \[[@B4]\]. Endogenous GLP-1 is metabolised rapidly to its so-called inactive metabolite by the ubiquitous enzyme dipeptyl-peptidase-4 (DPP-4), the half-life of native GLP-1 being \~1 to 2 minutes \[[@B5]\]. While this factor essentially precludes the use of exogenous GLP-1 in ambulant patients, rapid metabolism of an agent may be a desirable pharmacokinetic property in the hospitalised patient. Accordingly, our group and others have explored the effects of exogenous GLP-1 in a variety of hospitalised, adult patients \[[@B6]-[@B10]\].

Using a prospective, randomised, open-label, design, Mecott and colleagues compared an intervention (exenatide ± insulin) with a control (intensive insulin therapy) in patients receiving small intestinal nutrient. The authors report that the intervention decreased insulin requirements while comparable glycaemic control was achieved. The therapeutic use of GLP-1 in critically ill patients is inherently attractive as it does not substantially increase the risk of hypoglycaemia \[[@B11]\]. In addition, GLP-1 therapies show reduced glycaemic variability when compared with insulin in ambulant diabetic patients \[[@B11]\].

Strengths of the study are the evaluation of a GLP-1-based therapy in a new population (paediatric) that has suffered a specific insult (burns), and the prolonged duration of evaluation (up to 28 days). Finally, and perhaps most significantly, the investigators have elected to use a GLP-1 analogue (exenatide) rather than the synthetic peptide. The major advantages of exenatide when compared with GLP-1 are that it can be administered intermittently, as well as its cheaper price and ready availability (Table [1](#T1){ref-type="table"}).

###### 

Comparison between GLP-1, GLP-1 analogues and DPP-4 inhibitors

                                                   GLP-1               GLP-1 analogues   DPP-4 inhibitors
  ------------------------------------------------ ------------------- ----------------- -------------------------
  Name(s)                                          GLP-1-(7-36)NH~2~   Exenatide         Sitagliptin
                                                                       Liraglutide       Vildagliptin
                                                                                         Saxagliptin
  Administration                                   Intravenous         Subcutaneous      Oral
  Studied in the critically ill patient            Yes                 Yes               No
  Current cost                                     Prohibitive         Expensive         Expensive
  Availability                                     Limited             Yes               Yes
  Half-life                                        1 to 2 minutes      2 to 15 hours     2 to 14 hours
  Additional effects mediated via inactive GLP-1   Yes                 No                No
  Nausea                                           Yes                 Yes               No
  Weight                                           Loss                Loss              Weight neutral
  Gastric emptying                                 Slows               Slows             Minimal, if any, effect

DPP-4, dipeptyl-peptidase-4; GLP-1, glucagon-like peptide-1.

Limitations of the study, which are largely acknowledged by the authors, include its open-label design and the relatively small number of subjects studied, with the consequent potential for type 2 errors. The authors reported that the use of the GLP-1 analogue failed to reduce hypoglycaemic episodes and glycaemic variability. However, the lack of effect on variability and hypoglycaemia may reflect administration of exenatide ± insulin, rather than using exenatide as a single agent. Plasma exenatide concentrations were not reported, and it should be recognised that concentrations may not be predictable in these subjects - since, even in healthy subjects, exenatide has a biological half-life of \~3 hours and large fluctuations in plasma levels occur with twice-daily subcutaneous administration. Furthermore, given the limited information on the mechanisms of glucose-lowering in the critically ill patient, measurement of insulin and/or C-peptide, as well as glucagon, would have been valuable.

Exendin-4 was isolated originally from the saliva of the Gila monster (*Heloderma suspectum*), a slow-moving venomous lizard native to the United States and Mexico. The Gila monster eats only 5 to 10 times per year and a meal causes a substantial postprandial increase in plasma exendin-4 concentrations \[[@B12]\]. Exendin-4 shares \~50% amino acid sequence identity with human GLP-1 and binds to the pancreatic GLP-1 receptor *in vitro*. Importantly, exendin-4 is resistant to DPP-4 inactivation, thereby having a prolonged duration of action \[[@B12]\]. Exenatide, a synthetic form of exendin-4, has been shown to reduce fasting and postprandial glucose via glucose-dependent stimulation of insulin and suppression of glucagon secretion, as well as slowing gastric emptying \[[@B13]\]. The latter is probably the dominant mechanism to account for glucose lowering after oral or intragastric meals in healthy subjects, type 2 diabetic patients, and those critically ill patients in whom gastric emptying is normal \[[@B10],[@B13]\]. GLP-1 analogues with half-lives between 12 hours and 3 to 4 days have been recently developed. These analogues have less variation in plasma concentrations after once-daily (for example, liraglutide) or weekly (sustained release exenatide) administration than twice a day dosing (exenatide). Oral drugs that inactivate the DPP-4 enzyme (DPP-4 inhibitors) - thereby attenuating metabolism and increasing the availability of endogenous GLP-1 and GIP - have also entered the clinical domain (Table [1](#T1){ref-type="table"}).

In the study of Mecott and colleagues, exenetide was well tolerated; but given the adverse effects associated with its use in ambulant diabetic patients, ongoing vigilance is warranted. These adverse effects include nausea and vomiting (usually transient) \[[@B14]\], as well as modest weight loss that occurs, and is frequently desirable, in ambulant type 2 diabetic patients \[[@B14]\], but may be detrimental in the critically ill patient. The potential association between GLP-1 analogues and pancreatitis remains uncertain \[[@B14]\]. Lastly, the investigators did not measure anti-exenatide antibodies or plasma calcitonin concentrations, but the significance of anti-exenatide antibiodies or mild increases in calcitonin concentrations is unclear \[[@B14]\].

Albeit preliminary, the present study represents part of a growing interest in the use of incretins, or incretin mimetics, for the management of hyperglycaemia in hospitalised patients \[[@B15]\]. The desirable blood glucose range in this group remains contentious, but, as with recent studies in ambulant type 2 diabetic patients, there seems to be minimal, or no, advantage in targeting glycaemia at the lower end of the fasting normal range. Rather, the latter may well be deleterious \[[@B16]\]. Because the glucose-lowering effect of GLP-1 is glucose dependent, there is likely to be a threshold - perhaps about 7 to 8 mmol/l - beyond which further reductions will only occur if exogenous insulin is co-administered. In addition to identifying the optimal glycaemic range, future studies should focus on the following: which of the incretin agents is most useful in the critically ill patient; whether these agents should be used in combination with insulin, or as single-agent therapy; and identification of the patient group most likely to benefit from administration of incretin mimetics.
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